Zobrazeno 1 - 10
of 66
pro vyhledávání: ''
Autor:
Elizabeth Blackwood, Antoine Hollebecque, Kelly DuPree, Xuyang Lu, Sami Mahrus, Sophie Postel-Vinay, Jennifer L. Schutzman, Elaine Murray, Erika Hamilton, Sara M. Tolaney, A. Moein, Michael Tagen, J. R. Infante, Antoine Italiano, J. Epler, Kathleen N. Moore, Maud Toulmonde, Jean-Charles Soria, Jennifer O. Lauchle, Geoffrey I. Shapiro, Patricia LoRusso, Franklin Peale, Sophie Cousin
Publikováno v:
Annals of Oncology. 29:1304-1311
Background Checkpoint kinase 1 (Chk1) inhibition following chemotherapy-elicited DNA damage overrides cell cycle arrest and induces mitotic catastrophe and cell death. GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in
Autor:
Frank Mayer, J. von Pawel, S.J. Salamone, Niels Reinmuth, Juergen R. Fischer, H.-G. Kopp, Markus Joerger, Andrea Henrich, W. Eberhardt, M Kimmich, Charlotte Kloft, Max Roessler, Lothar Mueller, Ulrich Jaehde, Martin Reck, M.C. Miller, Dirk Behringer, Stefanie Kraff, Ralf A. Hilger, Yon-Dschun Ko, Thomas Gauler, B. Moritz
Publikováno v:
Annals of Oncology. 27:1895-1902
BACKGROUND Variable chemotherapy exposure may cause toxicity or lack of efficacy. This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing in patients with advanced non-small-cell lung cancer (NSCLC) to avoid supra- or s
Autor:
S. Thayer, Patricia LoRusso, W.M. Kavanaugh, Kyri Papadopoulos, Amita Patnaik, A.T. Gemo, J. Zanghi, K. Wilson, Harold N. Keer, Anthony W. Tolcher
Publikováno v:
Annals of Oncology. 27:526-532
Background Fibroblast growth factors (FGFs) play important roles in multiple cancers by supporting tumor growth and angiogenesis. FP-1039 (GSK3052230) is a FGF ligand trap consisting of the extracellular domain of FGF receptor 1 (FGFR1) fused with th
Autor:
K. Sugio, Narikazu Boku, K. Muro, Haruyasu Murakami, Shiro Akinaga, Hisateru Yasui, Yasuhiro Koh, Tateaki Naito, Nobuyuki Yamamoto, Tsuyoshi Takahashi, Tomonori Hirashima, Tomohiro Nishina
Publikováno v:
Annals of Oncology. 24:1653-1659
Background Tivantinib (formerly ARQ 197) is a selective inhibitor of c-Met mainly metabolized by CYP2C19. CYP2C19 is known for genetic polymorphisms, and ∼20% of Asians are poor metabolizers (PMs), while others are extensive metabolizers (EMs). In
Autor:
Elizabeth Eisenhauer, Joana Sederias, J. Mazurka, Amit M. Oza, A. Doyle, H. Hirte, Christian K. Kollmannsberger, Laurie Elit, Kim N. Chi, W. Walsh, Lillian L. Siu
Publikováno v:
Ann Oncol
Background The purpose of the study was to assess the safety, tolerability, recommended phase II dose (RPTD), and preliminary antitumor activity of the combination of carboplatin–paclitaxel (Taxol)–temsirolimus. Materials and methods: Patients wi
Autor:
Mercedes Martinez-Villacampa, Matilde Navarro, Margarita Reboredo, E. Aranda, Manuel Valladares, Juan Carlos Cámara, M. Constenla, Eugenio Marcuello, Alfredo Carrato, Manuel Benavides, R. Dueñas, A. Gomez, Eduardo Díaz-Rubio, B. Massutti
Publikováno v:
ANNALS OF ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background: Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC). The aim of this study was to demonstrate that a regimen
Autor:
Daniel A. Laheru, Wells A. Messersmith, Manuel Hidalgo, Wen Wee Ma, Antonio Jimeno, Carlton K. K. Lee, Ross C. Donehower, Sharyn D. Baker
Publikováno v:
Annals of Oncology. 19:374-379
Background Troxacitabine is a novel L-nucleoside analogue. Preclinical studies showed improved activity with infusions of at least 3 days compared with bolus regimens, especially at concentrations >20 ng/ml. This phase I study tested the feasibility
Autor:
Nancy L. Bartlett, Bruce D. Cheson, George P. Canellos, Jeffrey L. Johnson, Andrew D. Zelenetz, K. van Besien, KB Johnson, Jonathan W. Friedberg, Donna Niedzwiecki
Publikováno v:
Annals of Oncology. 18:1071-1079
Background: Because of high single-agent activity and modest toxicity, we hypothesized the combination of gemcitabine (G), vinorelbine (V), and pegylated liposomal doxorubicin (D) would be an effective salvage therapy for Hodgkin's lymphoma (HL). Pat
Autor:
Ralf A. Hilger, P. Kupsch, Dirk Strumberg, C. Flashar, Max E. Scheulen, Brian Schwartz, M. Ludwig, Bernhard F. Henning, Grubert M, Heike Richly, E. Brendel, K. Passarge, Rudolf Voigtmann, Olaf Christensen, Siegfried Seeber
Publikováno v:
Annals of Oncology. 17:866-873
Sorafenib (BAY 43-9006), a novel, oral multi-kinase inhibitor, blocks serine/threonine and receptor tyrosine kinases in the tumor and vasculature. Sorafenib demonstrated single-agent activity in Phase I studies, and was tolerated and inhibited tumor
Autor:
T. Hotta, T. Seriu, Yasutsuna Sasaki, Takashi Watanabe, Kensei Tobinai, Yoshiaki Ogawa, Michinori Ogura, Hironobu Minami, Yasuo Morishima
Publikováno v:
Annals of Oncology. 17:330-333
Background: The primary objective of this study was to investigate the tolerability, efficacy and pharmacokinetic profile of oral fludarabine phosphate in relapsed patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL). Patients and methods: Pa